Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PTGX NASDAQ:RXRX NASDAQ:RYTM NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePTGXProtagonist Therapeutics$105.55+1.6%$100.58$43.47▼$107.84$6.68B1.89620,956 shs426,528 shsRXRXRecursion Pharmaceuticals$3.04-0.3%$3.35$2.80▼$7.18$1.62B1.0512.52 million shs14.86 million shsRYTMRhythm Pharmaceuticals$93.63-0.1%$87.64$57.20▼$122.20$6.42B1.94796,896 shs842,615 shsTGTXTG Therapeutics$40.79-4.4%$33.98$25.28▼$44.65$6.53B1.682.46 million shs1.54 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePTGXProtagonist Therapeutics+1.61%+6.78%+0.79%+29.53%+141.15%RXRXRecursion Pharmaceuticals-0.33%-7.03%-14.12%-12.89%-29.47%RYTMRhythm Pharmaceuticals-0.10%-2.70%+7.28%-4.53%+63.46%TGTXTG Therapeutics-4.36%-5.21%+18.03%+43.12%+22.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePTGXProtagonist Therapeutics$105.55+1.6%$100.58$43.47▼$107.84$6.68B1.89620,956 shs426,528 shsRXRXRecursion Pharmaceuticals$3.04-0.3%$3.35$2.80▼$7.18$1.62B1.0512.52 million shs14.86 million shsRYTMRhythm Pharmaceuticals$93.63-0.1%$87.64$57.20▼$122.20$6.42B1.94796,896 shs842,615 shsTGTXTG Therapeutics$40.79-4.4%$33.98$25.28▼$44.65$6.53B1.682.46 million shs1.54 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePTGXProtagonist Therapeutics+1.61%+6.78%+0.79%+29.53%+141.15%RXRXRecursion Pharmaceuticals-0.33%-7.03%-14.12%-12.89%-29.47%RYTMRhythm Pharmaceuticals-0.10%-2.70%+7.28%-4.53%+63.46%TGTXTG Therapeutics-4.36%-5.21%+18.03%+43.12%+22.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePTGXProtagonist Therapeutics 2.80Moderate Buy$113.697.71% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10166.45% UpsideRYTMRhythm Pharmaceuticals 2.84Moderate Buy$131.8140.78% UpsideTGTXTG Therapeutics 2.57Moderate Buy$52.5028.71% UpsideCurrent Analyst Ratings BreakdownLatest RXRX, RYTM, TGTX, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/7/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $143.005/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/6/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $70.005/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.005/6/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$136.00 ➝ $137.005/6/2026RYTMRhythm Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$143.00 ➝ $144.005/1/2026TGTXTG Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPTGXProtagonist Therapeutics$46.02M147.50N/AN/A$10.19 per share10.36RXRXRecursion Pharmaceuticals$65.74M24.50N/AN/A$1.93 per share1.58RYTMRhythm Pharmaceuticals$189.76M33.81N/AN/A$1.79 per share52.31TGTXTG Therapeutics$616.29M10.13$2.68 per share15.22$3.81 per share10.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%N/ARXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%N/ARYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%N/ATGTXTG Therapeutics$447.18M$2.8614.2614.67N/A65.95%88.73%43.44%8/3/2026 (Estimated)Latest RXRX, RYTM, TGTX, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million2/26/2026Q4 2025RYTMRhythm Pharmaceuticals-$0.79-$0.73+$0.06-$0.73$56.16 million$57.25 million2/26/2026Q4 2025TGTXTG Therapeutics$0.35$0.14-$0.21$0.14$192.15 million$192.57 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 million2/25/2026Q4 2025RXRXRecursion Pharmaceuticals-$0.28-$0.21+$0.07-$0.21$24.56 million$35.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPTGXProtagonist TherapeuticsN/A17.7617.76RXRXRecursion Pharmaceuticals0.015.475.47RYTMRhythm PharmaceuticalsN/A4.173.89TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPTGXProtagonist Therapeutics98.63%RXRXRecursion Pharmaceuticals89.06%RYTMRhythm PharmaceuticalsN/ATGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipPTGXProtagonist Therapeutics5.19%RXRXRecursion Pharmaceuticals8.43%RYTMRhythm Pharmaceuticals5.90%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million485.23 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableTGTXTG Therapeutics290153.08 million136.80 millionOptionableRXRX, RYTM, TGTX, and PTGX HeadlinesRecent News About These CompaniesTG Therapeutics Stock Story Gains Interest In Nasdaq IndexMay 13 at 11:08 PM | kalkinemedia.comKTG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They AppearMay 13 at 11:08 PM | finance.yahoo.comHistoric Signal Says This Biotech OutperformsMay 11, 2026 | schaeffersresearch.comWhy TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI StrengthMay 11, 2026 | finance.yahoo.comAssessing TG Therapeutics (TGTX) Valuation After Recent Share Price MomentumMay 10, 2026 | finance.yahoo.comQ2 EPS Estimates for TG Therapeutics Increased by AnalystMay 8, 2026 | marketbeat.comTGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewMay 7, 2026 | zacks.comTG Therapeutics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comTG Therapeutics: Q1 Earnings SnapshotMay 6, 2026 | seattlepi.comSTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | markets.businessinsider.comTG Therapeutics (TGTX) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings missMay 6, 2026 | msn.comTG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings ResultsMay 6, 2026 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Time to Buy?May 6, 2026 | marketbeat.comTG Therapeutics (TGTX) Q1 Earnings Lag EstimatesMay 6, 2026 | zacks.comVanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTXMay 6, 2026 | marketbeat.comTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | globenewswire.comTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateApril 30, 2026 | globenewswire.comPictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTXApril 30, 2026 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by AnalystsApril 30, 2026 | marketbeat.comFortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings GrowthApril 28, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXRX, RYTM, TGTX, and PTGX Company DescriptionsProtagonist Therapeutics NASDAQ:PTGX$105.55 +1.67 (+1.61%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$104.16 -1.40 (-1.32%) As of 07:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Recursion Pharmaceuticals NASDAQ:RXRX$3.04 -0.01 (-0.33%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$3.00 -0.04 (-1.48%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Rhythm Pharmaceuticals NASDAQ:RYTM$93.63 -0.09 (-0.10%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$93.62 -0.02 (-0.02%) As of 07:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.TG Therapeutics NASDAQ:TGTX$40.79 -1.86 (-4.36%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$40.70 -0.09 (-0.23%) As of 07:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
